Baricitinib Impurities are the unwanted substances that are present in Baricitinib drug products. These impurities may be formed during the manufacturing process or may be introduced during the storage or handling of the drug product. The presence of these impurities can affect the efficacy and safety of the drug product, and therefore it is essential to monitor and control them. The regulatory authorities have set limits for these impurities, and drug manufacturers must comply with these limits to ensure the quality and safety of the drug product.
